INTRODUCTION
Melanoma comprises several tumor subtypes with distinct clinical behaviors and genetic makeups. 1 In contrast to melanoma arising from non-chronically sun-damaged skin, which demonstrates BRAF mutations frequently, mucosal, acral, and chronically sun-damaged (CSD) melanoma harbor mutations in the KIT oncogene.
KIT plays a role in normal melanocyte development and is upstream of pathways important for differentiation, proliferation, and survival. [1] [2] [3] KIT-mutant (KIT1) melanoma represents approximately 3% of melanoma. 1, [4] [5] [6] [7] [8] KIT1 is identified in 20% of mucosal or acral melanoma. 1, [4] [5] [6] 9 Although mutations in CSD melanoma were initially reported to occur at similar frequencies, more recent data have demonstrated that the KIT1 rate in CSD melanoma is lower (approximately 2%). 10 Even though initial studies with KIT inhibitors in an unselected population did not demonstrate a clinical benefit, 11, 12 clinical activity has been observed in prospective trials with KIT inhibitors in KIT1 acral, mucosal, and/or CSD melanoma. These include trials with imatinib, 5, 6, 9 nilotinib after prior KIT inhibition, 13 and sunitinib. 7 Although the response rates are approximately 16% to 23% with imatinib for patients with KIT1 acral, mucosal, and/or CSD melanoma, the response rate is approximately 40% for patients with exon 11 or 13 KIT1 melanoma (approximately 70% of KIT mutations in melanoma). 5, 6, 9 Since 2013, imatinib has been included in the National Comprehensive Cancer Network clinical practice guidelines for KIT1 melanoma.
Dasatinib (Sprycel; BMS-354285) targets KIT, platelet-derived growth factor receptor b, BCR-ABL, and the SRC family. Dasatinib potently inhibits wild-type KIT (KIT-), juxtamembrane domain mutant KIT autophosphorylation, and KIT-dependent activation of downstream pathways.
14 Preclinical data support the idea that dasatinib is a potent inhibitor in the setting of imatinib-resistant KIT activation loop mutation. 14 In vitro drug testing has revealed that dasatinib is a more potent inhibitor of cell proliferation than imatinib and nilotinib in Ba/F3 cell lines expressing KIT1 isoform L576P (exon 11), the most frequently detected KIT mutation in melanoma. 15 In WM3211 cells, which also harbor L576P KIT mutations, dasatinib inhibits cell viability in comparison with imatinib, nilotinib, and sorafenib. 16 Dasatinib has demonstrated activity against platelet-derived growth factor receptor, which is often co-amplified with KIT in these rare melanoma subtypes, 17 as well as SRC family kinases, which are associated with metastatic potential. [18] [19] [20] [21] On the basis of these preclinical studies, we initiated the ECOG-ACRIN E2607 trial to investigate the activity of dasatinib in patients with mucosal, acral, or CSD cutaneous melanoma. After stage I, the study was modified to enroll only patients with KIT1 tumors. Vulvovaginal melanoma was substituted for CSD melanoma because of the low KIT1 rate identified in CSD melanoma. 10 We report the efficacy and safety of dasatinib in patients accrued to E2607.
MATERIALS AND METHODS

Eligibility Criteria
The initial E2607 eligibility criteria included histologically or cytologically confirmed unresectable melanoma of the following subtypes: 1) acral (ie, occurring on the palms, soles, or subungual sites), 2) mucosal, and 3) solar (defined as cutaneous melanoma with chronic sun damage, ie, the presence of solar elastosis in the skin adjacent to the melanoma).
1 Solar elastosis was determined by local pathology on the primary tumor. The trial was amended in November 2011 to exclude CSD melanoma and to include patients with KIT1 melanoma arising from the vagina and/or vulva. Although vulvovaginal melanoma constitutes approximately 18% of mucosal melanoma, the KIT1 rate in this subtype is approximately 27%, whereas the rate is 12% for those arising from the head and neck or anal region. 22, 23 The Gynecologic Oncology Group endorsed this study to aid in accruing these patients.
Additional entry criteria included the following: measurable disease per the Response Evaluation Criteria in Solid Tumors (version 1.0); an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; and appropriate hematologic, renal, and liver function. Both treatment-naive patients and previously treated patients, including those who had previously received limb perfusion, chemotherapy, or immunotherapy, were eligible. Exclusion criteria included uveal melanoma, prior c-KITtargeted therapy (ie, imatinib, nilotinib, or sunitinib), any evidence of bleeding diathesis, a prolonged QTc (480 milliseconds), and any underlying cardiopulmonary dysfunction. Patients with brain metastases were allowed as long as they had completed radiation or surgical treatment for brain lesions without evidence of progression for at least 8 weeks and no longer required corticosteroids.
Treatment
Patients were assigned to receive 70 mg of dasatinib by mouth twice daily on an open-label, single-arm basis with adjustments for toxicity. The medication was taken once in the morning and once in the evening with or without food. The cycle length of the dasatinib treatment was 21 days. There were no breaks between cycles. The study was approved by an institutional review board or at each participating site, and all patients provided written informed consent before enrollment.
KIT Mutation Detection
The KIT mutational status was determined by polymerase chain reaction, and sequencing was performed either locally or centrally at Massachusetts General Hospital (under supervision by A.J.I.); exons 9, 11, 13, 17, and 18 were evaluated for mutations. If the local analysis identified c-KIT1 in an exon not listed here, prior approval was required centrally. With central testing, the resulting amplicons were evaluated for mutations with bidirectional Sanger sequencing via a Big Dye Terminator V1.1 cycle sequencing kit and an automated ABI 3730 DNA analyzer (Applied Biosystems, Foster City, Calif). The following mutations identified in melanoma were evaluated [24] [25] [26] [27] : exon 11 (Y553N, V559A, N566D, and L576P), exon 13 (R634W and K642E), exon 17 (D816H), and exon 18 (A829P). A sample would be considered KIT1 if a second round of polymerase chain reaction amplification and sequencing confirmed the mutant sequence.
Endpoints, Assessment, and Toxicity
The primary endpoint was response rate (complete and partial responses). Secondary endpoints included the duration of response for responders, progression-free survival (PFS), overall survival (OS), and the safety profile of dasatinib. PFS was defined as the time from the initiation of dasatinib until objective tumor progression or death. OS was defined as the time from dasatinib initiation until death from any cause or last follow-up. Systemic imaging with chest, abdominal, and pelvic computed tomography was performed every 6 weeks (2 cycles). Baseline brain imaging was conducted for all patients. Toxicities and adverse events were classified according to the Common Terminology Criteria for Adverse Events (version 3.0). Study participation was discontinued if adverse effects persisted.
Study Design and Analysis
E2607 was originally designed to evaluate the response rates in 56 patients with KIT1 and KIT-acral, mucosal, or CSD metastatic melanoma.
Accrual was suspended in December 2010 to allow an analysis of stage I. The interim analysis indicated that the response rate was low in KIT-patients. This led to a design change to only enroll patients with acral, mucosal, or vulvovaginal melanoma that were KIT1 as determined either locally or centrally. Patients with CSD melanoma were no longer eligible. The revised study was reactivated in November 2011.
For the amended protocol (called stage II), the plan was to accrue a maximum of 30 patients (for 28 eligible patients) with KIT1 melanoma in a 2-stage design. 28 If dasatinib could improve the response rate from 15% to 37% among KIT1 cases, dasatinib would be considered a promising agent. In the first stage of stage II, 15 cases (for 14 eligible patients) would be accrued. If there were at least 3 responses, stage II accrual would continue to 30 patients. If there were at least 7 responses, this would be considered successful. This design would provide 90% power with a 1-sided type I error rate of .10.
The response rate was estimated, and the 90% confidence interval (CI) was presented. For the stage II response rate, the 2-stage adjusted CI was provided. The distributions of PFS and OS were estimated with the Kaplan-Meier method, 29 and 95% CIs were calculated with Greenwood's formula. All reported P values were for 2-sided tests.
RESULTS
Patient Population
Between May 2009 and December 2010, 57 patients were accrued to stage I of E2607 ( [see online supporting information]). Five of the 57 patients were ineligible (3 with newly diagnosed brain metastases and 2 with inadequate baseline measurements), and 1 never started dasatinib. Stage II opened in November 2011 and received an endorsement through the Cancer Trials Support Unit in March 2013, with 290 institutions opening the trial at some point during the trial. Among the 15 patients enrolled in the first stage of stage II, there were at least 3 partial responses. This allowed continuation to the planned total of 30 patients for stage II. However, because of slow accrual, stage II accrual was terminated with a total of 24 patients in December 2015. One of these patients had inadequate baseline measurements, and 1 patient refused dasatinib. Thus, eligible and treated patients (51 in stage I and 22 in stage II) were considered analyzable and were included in the main efficacy analysis. For the toxicity analysis, 75 treated patients were included.
The baseline clinical and pathological features of the analyzable patients are described in Table 1 
KIT Mutation Status
Three of the patients accrued in stage I had KIT1 tumors (Table 2) , 42 patients had tumors that were KIT-, and 6 patients underwent mutation testing that was attempted and failed. For stage I, all mutations were assessed centrally. One of the patients with KIT1 melanoma had acral melanoma, and 2 had mucosal melanoma. In stage II, the KIT mutation status was accessed locally, and all 22 evaluable tumors were KIT1 (8 acral tumors, 6 mucosal tumors, and 8 vulvovaginal tumors). Fourteen of those from stage II had only an exon 11 mutation (7 with an L576P mutation), 2 had an exon 13 mutation, and 3 had exon 17 mutations (Table 2) . Three patients had more than 1 KIT mutation detected in metastatic tissue: 1) an exon 11 mutation (Y568D) and an exon 13 mutation (N655T), 2) an exon 11 mutation (D572E) and exon 17 mutations (D816Y and D820E), and 3) an exon 11 mutation (D759 deletion) and an exon 17 mutation (D816H). Clinical Outcomes
Response rate
The median follow-up was 59.5 months (range: 3.9-64 months) for patients from stage I and 23.2 months (range: 6-43 months) for patients from stage II. In terms of the best response in stage I, 3 of 51 patients achieved a partial response (5.9%; 90% CI, 1.6%-14.5%); all 3 patients were KIT-(2 with mucosal melanoma and 1 with CSD melanoma). Thirteen patients had stable disease (25.5%), 29 had disease progression (56.9%), and 6 were unevaluable (11.8%; Table 3 ). Four of the 22 patients from stage II had a partial response (18.2%; 2-stage adjusted 90% CI, 10.4%-46.6%), 7 had stable disease (31.8%), 6 progressed (27.3%), and 5 were unknown/unevaluable (22.7%). Among those with a partial response in stage II, 3 had acral melanoma (2 with an exon 11 mutation and 1 with an exon 13 mutation), and 1 had mucosal melanoma (exon 11 mutation). For the 7 patients with a partial response, the median response duration was 4.2 months (range: 0-17.1 months). Notably, none of the 7 patients with an L576P mutation achieved a partial response. Among the 20 patients with an exon 11 and/or exon 13 KIT mutation from stage I or II (including the patient with dual exon 11 and 13 mutations), the partial response rate was 20% (90% CI, 7.1%-40.1%).
PFS
For the 73 evaluable patients, the median PFS was 2.1 months (95% CI, 1.5-2.9 months), as shown in Table 4 . When this was broken down by the KIT mutation status, the PFS for KIT1 melanoma (median, 2.7 months; 95% CI, 1.4-5.0 months) was not significantly different from the PFS for KIT-melanoma (median, 2.0 months; 95% CI, 1.5-2.9 months) or melanoma with an unknown KIT status (median, 1.6 months; 95% CI, 0.7-3.1 months; P 5 .11; Fig. 2A ). For those with exon 11 and/or exon 13 mutations, the median PFS was 4.7 months (95% CI, 1.6-5.6 months). When PFS was compared by subtype, acral patients numerically had longer PFS (median, 2.8 months; 95% CI, 1.6-5.7 months) than patients with mucosal (median, 2.5 months; 95% CI, 1.6-4.4 months), vulvovaginal (median, 2.0 months; 95% CI, 1.2-4.0 months), or CSD melanoma (median, 1.3 months; 95% CI, 1.2-2.1 months); however, the number of patients with these subtypes was small and did not reach statistical significance (P 5 .17; Fig. 2B ).
OS
Among the evaluable patients, all but 14 died (median OS, 7.5 months; 95% CI, 6.0-11.9 months; an unknown KIT status (median, 7.9 months; 95% CI, 2.4-27.6 months; P 5 .56; Fig. 2C ). For those with exon 11 and/or exon 13 mutations, the median OS was 12.3 months (95% CI, 4.7-29.7 months). OS for acral patients (median, 21.1 months; 95% CI, 7.6-28.6 months) was longer than OS for patients with the other subtypes: mucosal (median, 6.9 months; 95% CI, 4.7-10.5 months), vulvovaginal (median, 8.8 months; 95% CI, 4.0 months to not reached), and CSD (median, 6.0 months; 95% CI, 2.4-11.6 months). However, this difference was not statistically significant (P 5 .23; Fig. 2D ).
Toxicity
The starting dose of dasatinib was 70 mg orally twice a day. The worst degree of toxicity was grade 3 for 33 of 75 patients (44%). The following grade 3 events occurred in 2 or more patients: fatigue (n 5 10), dyspnea (n 5 9), nausea (n 5 8), anemia (n 5 5), pleural effusion (n 5 4), neutropenia (n 5 3), vomiting (n 5 3), anorexia (n 5 2), hypoxia (n 5 2), hypertension (n 5 2), lymphopenia (n 5 2), and myocardial infarction (n 5 2; Table 5 ). One patient had grade 4 dyspnea, and another had a grade 4 lipase elevation. Dasatinib was discontinued because of adverse events in 9 of the 75 patients (12%).
DISCUSSION
Although we observed clinical activity with dasatinib in patients with KIT1 melanoma, the response rate in E2607 was lower than expected. No complete responses were identified. The partial response rate was higher in those with KIT1 melanoma (18% in stage II; 2-stage adjusted 90% CI, 10.4%-46.6%) versus those with KITmelanoma (5.9% in stage I; 90% CI, 1.6%-14.5%). Among patients with exon 11 and/or 13 KIT mutations, the partial response rate was 20% (90% CI, 7.1%-40.1%). Thus, we failed to reject the null hypothesis and did not find a significant increase in the response rate. E2607 represents a large, collaborative effort to identify patients with this rare somatic mutation in melanoma. Stage II was discontinued early because of slow accrual. Because of the responses observed with other KIT inhibitors and the inclusion of imatinib in National Comprehensive Cancer Network guidelines, these factors also likely contributed to difficulty with enrollment. Although preclinical data suggested that dasatinib would demonstrate more clinical activity than other KIT inhibitors, 15, 16 these findings did not translate clinically. Although this study had a limited sample size and this prompts caution for comparisons of this trial with other relatively small studies with KIT-directed tyrosine kinase inhibitors, it was notable that no patients with L576P mutations responded to dasatinib. In gastrointestinal stromal tumors (GISTs), some exon 11 substitutions such as L576P are associated with a favorable prognosis. 30 In GISTs, approximately 90% of patients respond to imatinib with the presence of a KIT exon 11 mutation, and approximately 50% with an exon 9 mutation respond. 31 Although dasatinib demonstrated a response rate of 32% in a phase 2 trial of patients with imatinib and sunitinibrefractory GISTs, the prespecified 6-month PFS rate was not achieved. 32 Imatinib and sunitinib remain the only Food and Drug Administration-approved KIT-directed therapy for GISTs.
In addition to KIT, dasatinib inhibits other kinases, including SRC family kinases, platelet-derived growth factor receptor b, and EPHA2. SRC activation regulates melanoma proliferation and invasion. 33 This broad range of targets likely explains the 3 patients with KIT-melanoma who experienced a partial response to dasatinib. E2607 is in accordance with other trials of dasatinib in melanoma. In a phase 2 trial of patients with unresectable melanoma of cutaneous, mucosal, or ocular origin, 2 of 36 patients (5.6%) achieved a partial response: one KITand another KIT1 with a primary subungual melanoma (K462E mutation). 34 In a phase 1 trial of dasatinib plus dacarbazine, 4 of 29 evaluable patients (13.8%) had a partial response; all were KIT-except for 1 patient with an NRAS mutation. KIT1 status is associated with a worse prognosis in melanoma. 36 Compared with other mutations in melanoma that are associated with 1 or 2 hotspot mutations such as BRAF mutations, KIT mutations demonstrate a broader spectrum. 37 Although most of the KIT mutations in GISTs are deletions or insertions, the majority in melanoma are point mutations. No responses were seen in patients whose melanoma harbored common KIT mutations, including L576P and K642E mutations. In cell lines harboring an L576P mutation, dasatinib inhibited cellular proliferation and KIT phosphorylation to a greater degree than other KIT inhibitors. Although dasatinib is a promiscuous tyrosine kinase inhibitor, it is unclear why patients with this mutation did not respond. Instead, responses were identified in patients with tumors exhibiting less frequent mutations, including a P577-D579 deletion and dual exon 11 and 13 mutations. Biological significance has not been elucidated for a number of these less common KIT mutations, which may be more passenger in nature. Including these potentially biologically insignificant mutations may dampen the biological activity observed in a phase 2 trial.
In a secondary analysis, we explored whether there were any differences in PFS or OS for patients by the KIT status (KIT1 or KIT-) or melanoma subtype. No such differences were identified, albeit with the understanding that these subgroups were small and not prespecified. Notably, the majority of patients stopped therapy because of progression of disease. Approximately 12% of the patients discontinued therapy because of adverse events. Although there were no unexpected toxicities, it is worth noting that the side-effect profile, including pleural effusion and dyspnea, is different than that of other KIT inhibitors. Because of the relatively low rate of discontinuation, this does not explain the limited clinical activity.
In addition to the early end of the trial due to slow accrual, there were a number of study limitations. The treatments that patients received before and after joining E2607 were not well captured. This study was activated before the approval of anti-CTLA4 blockade and checkpoint inhibitors. Although there were likely a few patients who received these immunotherapeutic agents before or after E2607, the exact number is unclear. Recently, rates of single-agent activity in acral and mucosal melanoma with anti-PD-1 inhibition have been described as approximately 32% and 23%, respectively. 38 We did not collect tissue at baseline, on treatment, or at progression to assess for markers of response/resistance. Although there are a number of proposed mechanisms of secondary resistance to KIT inhibition, including secondary KIT or NRAS mutations 7 and the activation of downstream pathway signaling (eg, ERK and the PI3K/Akt pathway), 39 we were unable to explore these findings.
In summary, although the study closed early because of slow accrual, we observed modest clinical activity with dasatinib in patients with unresectable acral, mucosal, vulvovaginal, or CSD melanoma. Because of the clinical activity and minimal toxicity observed with imatinib, we conclude that, at this time, imatinib should remain the KIT inhibitor of choice for patients with unresectable KIT1 melanoma.
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